French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Thursday that it has entered into a strategic partnership with Orano Med, a developer of targeted alphatherapies in oncology and a subsidiary of the Orano Group, to develop innovative radioligand therapies for rare cancers.

This collaboration leverages Orano Med's expertise and radioligand pipeline and Sanofi's capabilities in drug discovery and development.

The partnership will focus on the discovery, design and clinical development of next-generation radioligand therapies based on lead-212 alpha-emitting isotopes. Sanofi's investment of EUR300m will further strengthen Orano Med and accelerate the development of its pipeline.